| Document |
Document Title |
|
WO/2022/195113A1 |
The present invention relates to the mesenchymal stem cells and their use in modulating the immune response following transplantation.
|
|
WO/2022/194267A1 |
A GPR84 antagonist, and a preparation method therefor and a use thereof, specifically a compound represented by formula (I), and a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof. The compou...
|
|
WO/2022/195119A1 |
The present invention relates to the field of stem cells and their use in processing ex vivo samples (e.g. blood samples). More specifically, the present invention relates to the use of mesenchymal stem cells in ECMO.
|
|
WO/2022/195963A1 |
The present invention provides: an agent for inhibiting microglial M1 polarization, the agent containing a substance that inhibits the expression of an inhibitor of nuclear factor kappa B kinase subunit epsilon (IKBKE) or inhibits kinase...
|
|
WO/2022/196719A1 |
The present invention provides: a chimeric receptor polypeptide which is useful in treatment of myasthenia gravis and in which an extracellular domain that includes an antigenic region linkable to an anti-human nicotinic acetylcholine re...
|
|
WO/2022/196668A1 |
The present invention provides a novel nucleic acid that suppresses the expression of ITGAV. The present invention indicates that a nucleic acid for a specific target sequence or a nucleic acid having a specific sequence has an excellent...
|
|
WO/2022/192964A1 |
The present invention provides methods for treating or preventing aggression, agitation, irritability and/or anger in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of For...
|
|
WO/2022/197627A1 |
The present disclosure provides methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of nevirapine and an effective amount of valacyclovir and/or nevirapine. ...
|
|
WO/2022/198099A1 |
Compositions of polynucleotide(s) are disclosed. A polynucleotide may encode for a polypeptide, protein, or functional fragment thereof associated with primary ciliary dyskinesia (PCD). Pharmaceutical compositions, kits, and methods for ...
|
|
WO/2022/197641A1 |
The present invention relates to 1H-pyrazolo[3,4-d]pyrimidin-6-yl- amine derivatives of formula (I) as hematopoietic progenitor kinase 1 (HPK1) modulators and/or inhibitors for the treatment of cancer and other diseases, such as e.g. vir...
|
|
WO/2022/196609A1 |
It is found that phenylbutyric acid (PBA) can prevent progressive retinal photoreceptor cell death and can prevent the deterioration in a visual function. On the basis of these findings, a pharmaceutical composition for preventing retina...
|
|
WO/2022/195102A1 |
The present invention relates to a compound having the following formula (I) wherein: - R and R' are, independently from each other, H or (C1-C6)alkyl groups, or form together with the carbon atoms carrying them a (C6-C10)aryl group; - R...
|
|
WO/2022/190317A1 |
[Problem] To provide a novel interferon production promoter. [Solution] A type-I and/or type-III interferon production promoter containing, as an active ingredient, Clostridium butyricum or a culture thereof.
|
|
WO/2022/191184A1 |
The present invention pertains to: a ghrelin receptor sensitivity-enhancing agent that contains ornithine or a salt thereof as an active ingredient; a composition that contains ornithine or a salt thereof as an active ingredient and that...
|
|
WO/2022/191107A1 |
The present invention provides a polymer represented by formula (I) etc., said polymer being useful as a drug carrier for effectively delivering a drug to a target site. (In the formula, each symbol is as defined in the description.)
|
|
WO/2022/190072A1 |
The present invention relates to an iron-based formulation and compositions thereof for use in a method for the treatment of a gastrointestinal inflammation, in a therapeutic or non-therapeutic treatment of an iron deficiency by administ...
|
|
WO/2022/191194A1 |
One of the problems addressed by the present invention is the provision of an agent for inhibiting renal damage induced by rhabdomyolysis. The present invention uses cilastatin or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/191183A1 |
The present invention relates to a composition that includes an intestinal bacterium belonging to the genus Veillonella having an inflammation-suppressing action or a substance having an inflammation-suppressing action derived from said ...
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/191182A1 |
The present invention pertains to: a composition that comprises an intestinal bacterium belonging to the phylum Bacteroides and having an inflammation reducing effect or a substance derived from the intestinal bacterium and having an inf...
|
|
WO/2022/191092A1 |
The present invention addresses the problem of providing a new method for increasing the intracerebral histamine concentration. The present invention provides a compound represented by general formula (I) or a salt thereof. [In the formu...
|
|
WO/2022/191320A1 |
The present invention addresses the problem of providing a technique for further promoting the proliferation of a plurality of major species of bacteria belonging to the genus Bifidobacterium in the intestinal flora. Oligosaccharides inc...
|
|
WO/2022/192745A1 |
Disclosed are compounds of Formula IIA, IIA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in metho...
|
|
WO/2022/191673A1 |
The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis, wherein the pharmaceutical composition contains exosomes surface-modified with vitamin A as active ingredients. The exosomes surface...
|
|
WO/2022/192163A1 |
The present invention discloses a recombinant adenovirus vector of a replication-defective human adenovirus (HAdv85C5) or a bovine adenovirus (BAdv85C5) comprising a recombinant adenovirus vector having a heterologous DNA segment encodin...
|
|
WO/2022/191193A1 |
One of the problems of the present invention is to provide an agent for preventing a kidney injury induced by a hemolytic reaction. In the present invention, cilastatin or a pharmaceutically acceptable salt thereof is used.
|
|
WO/2022/186290A1 |
The present invention addresses the problem of providing a peptide having excellent dipeptidyl peptidase-IV (DPP-IV) inhibitory activity. An oligopeptide including any of the sequences described in (a) to (h) below. These oligopeptides m...
|
|
WO/2022/187578A1 |
Methods and compositions related to improved solid dosage forms that facilitate the oral delivery of bacteria or agents of bacterial origin are provided herein.
|
|
WO/2022/187303A1 |
Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula (I). The compound may be administered as a composition, such...
|
|
WO/2022/185058A1 |
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inh...
|
|
WO/2022/184802A1 |
The direct delivery of antioxidant compounds (Vitamin B2, Vitamin C, beta-carotene, and Vitamin E) to the large intestine results in an increase in the population of Blautia spp. in the gut. People with lower amounts of Blautia spp. ofte...
|
|
WO/2022/185952A1 |
Provided is a therapeutic agent for the drug resistance of cells to microtubule inhibitors, the therapeutic agent containing a κ opioid receptor agonist.
|
|
WO/2022/183246A1 |
The present invention relates to compositions, methods and kits for the treatment and/or prevention and/or diagnosis of sepsis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment,...
|
|
WO/2022/185599A1 |
[Problem] The change in quality of hair with aging is one of problems particularly for women more than 40 years old. If the quality of hair can be improved effectively, the quality of life (QOL) can be further improved. The purpose of th...
|
|
WO/2022/186349A1 |
ADM and/or HHEX-highly expressing fibroblasts have been found as cells having lymphangiogenesis ability, and a means for treating fibrosis using a pharmaceutical composition containing said cells, a means for ameliorating a state in whic...
|
|
WO/2022/186350A1 |
The present invention provides a nucleic acid having excellent cell membrane penetrating activity. The present invention pertains to: a nucleic acid having a structure represented by general formula (A1) or (A2) [in the formulas, R0 repr...
|
|
WO/2022/185055A1 |
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inh...
|
|
WO/2022/186282A1 |
The present invention provides a new gene therapy method which is less invasive and is capable of providing a desired therapeutic effect on diabetes including T1D. Specifically, provided is a pancreatic β cell protecting/regenerating fo...
|
|
WO/2022/184018A1 |
An exogenous mitochondria vector, a complex, and a preparation method therefor and the use thereof. Specifically, an ex vivo exogenous mitochondria is modified by one or more materials with a good biocompatibility, the modified ex vivo e...
|
|
WO/2022/186391A1 |
The present invention provides a pharmaceutical composition for use in the reactivation of HIV latent infection, the pharmaceutical composition containing compounds represented by formulae (I)-(VII).
|
|
WO/2022/184176A1 |
Disclosed are a pharmaceutical composition containing ethanol and a use thereof. The pharmaceutical composition can be used in vivo for animals, and is prepared from the following raw material: ethanol having a concentration no lower tha...
|
|
WO/2022/186015A1 |
The present invention relates to a neuropsychological function improving agent for preventing and/or ameliorating symptoms and/or diseases caused by the deterioration of neuropsychological function, said agent containing soybean peptide ...
|
|
WO/2022/185742A1 |
A prophylactic or therapeutic composition for disseminated intravascular coagulation syndrome, the composition comprising, as an active ingredient, at least one selected from adenosine A2a receptor antagonists and dopamine D2-like recept...
|
|
WO/2022/185057A1 |
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibit...
|
|
WO/2022/186089A1 |
The purpose of the present invention is to provide a novel method for increasing the number of newly generated neurons in the adult brain, and to provide a polynucleotide, a vector, and a pharmaceutical composition for use in the method....
|
|
WO/2022/181438A1 |
The present invention addresses the problem of providing: a method for evaluating the xenobiotic response reaction inducibility of a sample of interest in skin in a simple and efficient manner without using an animal; a substance capable...
|
|
WO/2022/181622A1 |
A problem addressed by the present invention is to provide an agent for improving dryness in the oral cavity that improves dryness in the oral cavity. The agent for improving dryness in the oral cavity of the present invention includes a...
|
|
WO/2022/180764A1 |
The objective of the invention is to provide methods of using cross-species anti-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF...
|
|
WO/2022/181532A1 |
Provided is a method for inhibiting the function of myostatin. Provided are: an antisense oligonucleotide having a base length of 15-30 and a base sequence complementary to the target sequence of exon 3 of myostatin gene, the antisense o...
|
|
WO/2022/181514A1 |
The present invention provides an inhibitor for chronic myeloid leukemia (CML) stem cells, a medicinal composition for treating CML that has an effect of preventing CML relapse, a method for preventing CML relapse, and a method for evalu...
|
